RT Journal Article
T1 Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
A1 Marth, Christian
A1 Tarnawski, Rafal
A1 Tyulyandina, Alexandra
A1 Pignata, Sandro
A1 Gilbert, Lucy
A1 Kaen, Diego
A1 Rubio, M. Jesus
A1 Frentzas, Sophia
A1 Beiner, Mario
A1 Magallanes-Maciel, Manuel
A1 Farrelly, Laura
A1 Choi, Chel Hun
A1 Berger, Regina
A1 Lee, Christine
A1 Vulsteke, Christof
A1 Hasegawa, Kosei
A1 Braicu, Elena Ioanna
A1 Wu, Xiaohua
A1 McKenzie, Jodi
A1 Lee, John J.
A1 Makker, Vicky
AB Background Pembrolizumab plus lenvatinib is a novel combination with promising efficacy in patients with advanced and recurrent endometrial cancer. This combination demonstrated high objective response rates in a single-arm phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer (KEYNOTE-146/Study 111) after
PB Bmj publishing group
SN 1048-891X
YR 2021
FD 2021-11-18
LK https://hdl.handle.net/10668/25441
UL https://hdl.handle.net/10668/25441
LA en
DS RISalud
RD Apr 12, 2025